CRF announces late breaking trials & first report investigations to be presented at TCT 2011

The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific symposium. Presented in partnership with the American College of Cardiology (ACC), TCT 2011 is the world’s leading educational meeting specializing in interventional cardiovascular medicine and will take place November 7-11, 2011 in San Francisco.

The studies selected will shed new light on the effectiveness of minimally invasive techniques, pharmaceuticals, technologies and devices that show potential to treat or prevent heart disease, one of the leading causes of death globally. Once again, TCT 2011 is expected to be the location of groundbreaking scientific reporting that will modernize care for people with cardiovascular disease and other vascular health issues. 

Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Wednesday, November 9, Thursday, November 10, and Friday, November 11.

WEDNESDAY, NOVEMBER 9

Focus on PCI Pharmacology and Stent Thrombosis I

  • ADAPT-DES: A Large-Scale, Prospective, Multicenter Registry Examining the Relationship of Platelet Responsiveness and Stent Thrombosis After DES Implantation
  • DESERT: A Large-Scale, Case-Controlled, Multicenter Study Examining the Predictors of Stent Thrombosis
  • PARIS: A Larger-Scale, Prospective, Multicenter Registry Studying the Patterns of and Reasons for Nonadherence to Antiplatelet Agents in Stented Patients

Focus on PCI Pharmacology and Stent Thrombosis II

  • RAPID GENE: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in CYP2C19*2 Carriers Identified by Rapid Point-of-Care Genotyping
  • TRIGGER-PCI: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Clopidogrel-Hyporesponsive Patients with Stable Ischemic Heart Disease Undergoing Percutaneous Coronary Intervention
  • BRIDGE: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Intravenous Cangrelor in Patients Awaiting Surgery

THURSDAY, NOVEMBER 10

Focus on Transcatheter Aortic Valve Replacement

  • PARTNER Cohort B Two-Year: A Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement vs. Standard Therapy in Patients with Inoperable Aortic Stenosis
  • PARTNER Cohort A QOL: Quality-of-Life Analysis from a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement vs. Surgical Aortic Valve Replacement in High-Surgical-Risk Patients with Aortic Stenosis
  • PARTNER Cohort A CE: Cost-Effectiveness Analysis from a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement vs. Surgical Aortic Valve Replacement in High-Surgical-Risk Patients with Aortic Stenosis
  • STACCATO: A Prospective, Randomized Trial of Transapical Transcatheter Aortic Valve Replacement vs. Surgical Aortic Valve Replacement in Low-Surgical-Risk Elderly Patients with Aortic Stenosis

Focus on Primary PCI in STEMI

  • RIFLE STEACS: A Prospective, Randomized Trial of Radial vs. Femoral Vascular Access in Patients with ST-Segment Elevation Myocardial Infarction
  • MUSTELA: A Prospective, Randomized Trial of Thrombectomy vs. No Thrombectomy in Patients with ST-Segment Elevation Myocardial Infarction and Thrombus-Rich Lesions
  • DEB-AMI: A Prospective, Randomized Trial of Paclitaxel-Coated Balloons plus Bare Metal Stents vs. Paclitaxel-Eluting Stents vs. Bare Metal Stents Alone in Patients with ST-Segment Elevation Myocardial Infarction

FRIDAY, NOVEMBER 11

Focus on Novel Drug-Eluting Stents and Drug-Coated Balloons

  • EVOLVE: A Prospective, Randomized Trial of Two-Dose Formulations of a Bioabsorbable Polymer-Based Everolimus-Eluting Stent vs. a Durable Polymer-Based Everolimus-Eluting Stent
  • REMEDEE: A Prospective, Randomized Trial of a Combination Bioabsorbable Polymer-Based Anti-CD34 Antibody Sirolimus-Eluting Stent vs. a Durable Polymer-Based Paclitaxel-Eluting Stent
  • CRE8: A Prospective, Randomized Trial of a Carbofilm-Coated Stent Eluting Sirolimus from Abluminal Reservoirs vs. a Paclitaxel-Eluting Stent
  • PEPCAD-DES: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Uncoated Balloon Angioplasty in Patients with Restenosis of Drug-Eluting Stents

Focus on Optimal PCI

  • TWENTE: A Prospective, Randomized Trial of Zotarolimus-Eluting Stents and Everolimus-Eluting Stents in an Unselected Patients with Coronary Artery Disease
  • ROTAXUS: A Prospective, Randomized Trial of High-Speed Rotational Atherectomy Prior to Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary Artery Lesions
  • ADVISE: Validation of a Vasodilator Independent Measure of Coronary Fractional Flow Reserve

Focus on Peripheral Vascular Disease

  • COBRA: A Prospective, Randomized Trial of Cryoplasty vs. Conventional Balloon Post-dilatation of Nitinol Stents in the Superficial Femoral Artery of Patients with Diabetes Mellitus
  • PROFI: A Prospective, Randomized Trial of Proximal Balloon Occlusion vs. Distal Filter Embolic Protection in Patients Undergoing Carotid Stenting

To view the program update, visit:

http://www.tctconference.com/program.html

Receive updates on Twitter: https://twitter.com/TCTConference

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field.

For more information, visit www.crf.org.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Scientists identify novel entry receptors for SARS-CoV-2